Desflurane, once hailed as a revolutionary volatile anesthetic for its rapid onset and recovery times, is increasingly falling out of favor in modern anesthetic practice. The movement away from desflurane is driven by a combination of environmental concerns, the availability of more effective alternatives, and a reevaluation of its overall clinical benefits.
One of the primary reasons for this shift is desflurane's significant environmental impact. Desflurane is a potent greenhouse gas with a global warming potential over 2,500 times that of carbon dioxide, making it one of the most environmentally harmful anesthetic agents in clinical use. The healthcare industry has become increasingly aware of its carbon footprint, and anesthesia providers and institutions are being urged to adopt more sustainable practices, which include reducing or eliminating high-global-warming-potential substances like desflurane.
The development and refinement of other inhaled anesthetics have facilitated the movement away from desflurane. Sevoflurane offers many of the same advantages — including rapid induction and emergence — with far fewer environmental drawbacks. Sevoflurane is well tolerated by patients, has a relatively low blood-gas partition coefficient, and is associated with less airway irritation.
Isoflurane, while slower in onset and recovery compared to both desflurane and sevoflurane, remains a reliable and cost-effective option, particularly in settings where rapid turnover is less critical. Its global warming potential is substantially lower than that of desflurane, making it a more environmentally responsible choice.
The increased availability and use of total intravenous anesthesia (TIVA) have also contributed to reduced reliance on volatile anesthetics like desflurane. TIVA offers several benefits including reduced postoperative nausea and vomiting, stable hemodynamics, and the complete elimination of anesthetic gas emissions into the operating room environment.
While desflurane was initially favored for its rapid onset and recovery characteristics, subsequent research has led to a reassessment of its clinical advantages. The rapid emergence it provides, while beneficial in certain situations, is not always necessary — particularly when other agents can achieve similar outcomes without the associated environmental costs.
Desflurane is also known to cause airway irritation, which can lead to coughing, laryngospasm, and increased sympathetic stimulation during induction and emergence. These side effects can be especially problematic in patients with reactive airways or those at cardiovascular risk. The availability of agents offering comparable benefits with fewer side effects has made desflurane less appealing in routine clinical practice.
The movement away from desflurane reflects a broader trend in anesthetic practice toward sustainability, patient safety, and cost-effectiveness. As environmental considerations become increasingly integrated into healthcare decision-making, desflurane's role in clinical anesthesia is likely to continue diminishing.